Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed

Boundless Bio, Inc.

2024-Q1 EPS reported -$12.27

Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.
Cash & investments $104.9M at March 31; April IPO grossed $100M from 6.25M shares, extending runway into 2H 2026.
BBI-355 POTENTIATE trial advanced to Part 2 combining with EGFR or FGFR inhibitors in oncogene-amplified tumors.
First patient dosed in BBI-825 Phase 1/2 STARMAP trial targeting resistance gene amplifications.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Boundless Bio, Inc. reported the quarter ended March 31, 2024 results: net income $15.4 million.

Period: the quarter ended March 31, 2024
Net income: $15.4 million
Result: reported results

Exact text from the filing

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

View on SEC.gov

Browse all earnings releases →

Boundless Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-058186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.